Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Human Papilloma Virus Cervical Cancer Oropharyngeal Cancer Anal Cancer Vaginal or Penile Cancer Age greater than or equal to 18 years Ability of subject to understand and the willingness to sign a written informed consent document Subjects with cytologically or histologically confirmed locally advanced or metastatic HPV associated malignancies including Non-Neuroendocrine Cervical cancers P16+ Oropharyngeal cancers Anal cancers Vulvar, vaginal, penile, squamous cell rectal and neuroendocrine cervical cancers Other locally advanced or metastatic solid tumors (e.g. lung, esophagus) that are known HPV+ Patients must have disease that is not amenable to potentially curative resection Subjects must have measurable disease  -Pregnant women are excluded from this study because this drug has not been tested in pregnant women and there is potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with M7824, breastfeeding should be discontinued if the mother is treated with M7824 Patients with prior investigational drug, chemotherapy, immunotherapy or any prior radiotherapy (except for palliative bone directed therapy) within the past 28 days prior to the first drug administration except if the investigator has assessed that all residual treatment-related toxicities have resolved or are minimal and feel the patient is otherwise suitable for enrollment. Patients may continue adjuvant hormonal therapy in the setting of a definitively treated cancer (e.g. breast) Major surgery within 28 days prior to the first drug administration (minimally invasive procedures such as diagnostic biopsies are permitted) Known intolerance to or life threatening side effects resulting from prior checkpoint inhibitor therapy Known active brain or central nervous system metastasis (less than 1 month out from definitive radiotherapy or surgery), seizures requiring anticonvulsant treatment (<3 months) or clinically significant cerebrovascular accident (<3 months). In order to be eligible patients must have repeat CNS imaging at least two months after definitive treatment showing stable CNS disease. Patients with evidence of intratumoral or peritumoral hemorrhage on baseline imaging are also excluded unless the hemorrhage is grade less than or equal to 1 and has been shown to be stable on two consecutive imaging scans Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent with exception of diabetes type I, eczema, vitiligo, alopecia, psoriasis, hypo or hyperthyroid disease or other mild autoimmune disorders not requiring immunosuppressive treatment Subjects requiring hormone replacement with corticosteroids are eligible if the steroids are administered only for the purpose of hormonal replacement and at doses less than or equal to 10 mg of prednisone or equivalent per day Administration of steroids for other conditions through a route known to result in a minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation) is acceptable